Hormone replacement therapy after a diagnosis of XXXX : @entity5 recurrence and mortality.

@entity1 @entity5 @entity797 @entity0
OBJECTIVE: To determine whether hormone replacement therapy (HRT) after treatment for @entity0 is associated with increased risk of recurrence and mortality. DESIGN: Retrospective observational study. @entity1 AND SETTING: Postmenopausal @entity1 diagnosed with @entity0 and treated by five Sydney doctors between 1964 and 1999. OUTCOME MEASURES: Times from diagnosis to @entity5 recurrence or new @entity0 , to death from all causes and to death from primary @entity5 were compared between @entity1 who used HRT for menopausal symptoms after diagnosis and those who did not. Relative risks (RRs) were determined from @entity797 regression analyses, adjusted for @entity1 and @entity5 characteristics. RESULTS: 1122 @entity1 were followed up for 0-36 years (median, 6.08 years); 154 were lost to follow-up. 286 @entity1 used HRT for menopausal symptoms for up to 26 years (median, 1.75 years). Compared with non-users, HRT users had reduced risk of @entity5 recurrence (adjusted relative risk [RR], 0.62; 95% CI, 0.43-0.87), all-cause mortality (RR, 0.34; 95% CI, 0.19-0.59) and death from primary @entity5 (RR, 0.40; 95% CI, 0.22-0.72). Continuous combined HRT was associated with a reduced risk of death from primary @entity5 (RR, 0.32; 95% CI, 0.12-0.88) and all-cause mortality (RR, 0.27; 95% CI, 0.10-0.73). CONCLUSION: HRT use for menopausal symptoms by @entity1 treated for primary @entity0 is not associated with an increased risk of @entity0 recurrence or shortened life expectancy.
